Skip to main content

Table 1 Characteristics of the included cohorts

From: Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts

Country

Breast cancer

Medication data

Mortality data

Additionala confounders

source

Diagnosis years

source

source

End f-up

Mean f-up (years)

Max f-up (years)

BC specific

Grade

Surg

Radio

Chemo

Tam

AI

Asp/statin

HRT

Comorbidity

Belgium

Belgian Cancer Registry

2007–2009

Intermutualistic Agency (health insurance records)

Kruispuntbank van de Sociale Zekerheid (social security records)

2014

6

8

No

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

No

Denmark

Danish Cancer Registryb

2000–2012

Danish National Prescription Registry

Danish Civil Registration System

2012

6

13

No

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yesc

England (UK)

National Cancer Data Repository

1998–2007

CPRD (GP records)

Office of National Statistics

2011

6

12

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

No

Yesd

The Netherlands

Eindhoven Cancer Registry

1999–2011

PHARMO (pharmacy records)

Central Bureau of Genealogy

2012

6

13

No

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yesg

Northern Ireland (UK)

Northern Ireland Cancer Registry

2009–2010

NIEPD (electronic dispensing database)

General Register Office for Northern Ireland

2013

4

5

Yes

No

Yes

N

Yes

Yes

Yes

Yes

No

No

Republic of Ireland

National Cancer Registry Ireland

2001–2010

GMSe (electronic prescribing database)

Central Statistics Office (Death Certificates)

2012

5

11

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yesf

Scotland (UK)

Scottish Cancer Registry

2009–2012

Prescribing Information System (electronic dispensing database)

National Records of Scotland Death Records

2015

4

6

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

No

Yesc

Sweden

Regional cancer registries in Norra, Uppsala/Örebro Stockholm/Gotland

2007–2012

The Prescribed Drug Register

Cause of death registry

2012

4

6

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yes

Yesc

  1. aIn fully adjusted analyses (presented in Tables 2 and 3), the model contains age at diagnosis, year of diagnosis, stage and the variables shown
  2. bOnly including stages 1–3
  3. cBased on hospital admissions
  4. dBased on GP diagnosis codes
  5. eGMS includes eligible patients based upon means test and age (all patients over 70 years old are included)
  6. fBased on RxRisk comorbidity score
  7. gFrom cancer registry records
  8. AI aromatase inhibitors, asp aspirin, BC breast cancer, chemo chemotherapy, CPRD clinical practice research datalink, f-up follow-up duration from diagnosis to death or censoring, GMS General Medical Services scheme, GP general practitioner, HRT hormone replacement therapy, max maximum, NIEPD Northern Ireland Electronic Prescribing Database, radio radiotherapy, surg surgery, tam tamoxifen